Cullinan Therapeutics
CGEM· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -15.0% in FY2025
Nadim Ahmed is the CEO of Cullinan Therapeutics and was paid $5.1M in FY2025 (Dec), down 34%.
Pay$100 in the stock at the end of FY21 → $67
Executives3
See all- 1Nadim AhmedPresident and Chief Executive OfficerFY2025
- 2Jeffrey Jones, M.D.Chief Medical OfficerFY2025
- 3Mary Kay FentonChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allCullinan Therapeutics paid its 3 named executives $9.4M in total in FY2025 (Dec). CEO Nadim Ahmed was paid $5.1M of that.
| Name | |||
|---|---|---|---|
| Nadim AhmedPresident and Chief Executive Officer | |||
| Jeffrey Jones, M.D.Chief Medical Officer | |||
| Mary Kay FentonChief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Cullinan Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Anne-Marie MartinDirector · 2 yr on the boardIndependentNominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 10, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | May 16, 2024 | FY2023 |
| Annual report | 10-K | Mar 14, 2024 | FY2023 |
